Inspira has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system to the UAE’s Ministry of Health and Prevention (MOHAP). Final approval is expected within days-marking a decisive step toward Gulf region expansion. $IINN Read more >>

Join our Inspiration! Inspira Technologies is seeking a Research Engineer to join our multidisciplinary research team developing advanced sensor technologies for real-time blood monitoring. Apply now >> inspira-technologies.com/careers/

Inspira has completed the clinical study for its HYLA™ non-invasive blood sensor, toward regulatory submission. Clinical and lab tests show between 95% to 99% accuracy. Inspira is now entering final validation and verification ahead of planned submission. $IINN

The HYLA™ Blood Monitoring System is designed to simplify workflows and reduce risks - providing continuous, real-time blood monitoring without manual sampling. With reliable in-line measurements and immediate data, HYLA™ can support clinicians in making timely, confident

HYLA™ is moving into its next phase. Following clinical trial results and ongoing lab tests, the HYLA™ non-invasive blood sensor has completed its clinical study, with accuracy results ranging between 95% to 99% across measured parameters. We are now entering the final

Inspira announced a strategic expansion of its blood laboratory capabilities, moving to a substantially larger state-of-the-art facility, planning to increase recruitment and upgrade instrumentation to support next-generation blood-analysis technologies. $IINN

Inspira has been granted a new patent in Japan for its Convertible Dual Lumen Cannula device, securing exclusive rights through 2041. This protection strengthens the IP foundation supporting the INSPIRA™ ART System and future disposable product strategies. $IINN

We’re pleased to welcome Ily Ben Yacov to Inspira as a Research Assistant. Ily joins our research team with hands-on experience in advanced imaging studies and a strong operational background. She will support experimental execution and data collection across our development

In critical care, every second matters - but blood data often arrives too late. HYLA™ blood monitoring is being developed to change that. It’s a smart, non-invasive blood sensor that continuously monitors key parameters in real time - without blood draws, without cuvettes, and

Happy Holidays to our global community. Wishing our partners, clinicians, and shareholders a season of light, gratitude, and meaningful progress. Thank you for being part of Inspira’s journey as we continue building and advancing our technology platform. Merry Christmas, and a

Happy New Year from Inspira Technologies!

Inspira announced a non-binding term sheet for a proposed acquisition of an advanced liquid biopsy diagnostics business alongside a concurrent $15M strategic equity investment into Inspira at $180M valuation subject to definitive agreements. $IINN Read more >>

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion. “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira”. $IINN Read more >> globenewswire.com/news-release/2…

Operational efficiency starts with smarter design. HYLA™ Blood Monitoring is developed to reduce complexity and cut consumable use, with one universal sensor that fits multiple systems and tubing sizes. No manual sampling. No cuvettes. This means simplified procurement, lower

$22.5M & $27M binding purchase orders advanced to final budgetary validation & fund allocation within gov’t authorities’ procurement processes. ~91% cleared commercial/admin review, prior to fund release & operational execution, subject to approvals. $IINN globenewswire.com/news-release/2…

FDA-cleared INSPIRA™ ART100 has completed a full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center. ~30 patients treated; ART100 systems incorporated into routine workflow. $IINN Read more >>

Validated next-gen standalone HYLA™: 94.2% accuracy for blood pCO₂ measurement. Provides continuous, non-invasive visibility. Pivot to standalone targets $48B heart-lung surgery market upon clearance. $IINN globenewswire.com/news-release/2…

Inspira received official approval from Clalit’s Medical Equipment Committee (world’s 2nd largest integrated HMO; $12B revenue), enabling INSPIRA™ ART100 for immediate procurement & operational use across Clalit's extensive medical ecosystem. $IINN Read more >>

Meet us at AmSECT 2026 (Austin, TX | March 25–29) at the Glo-Med Networks booth. We’ll be there throughout the conference to connect with the perfusion community and share the latest on INSPIRA™ ART100. To set up a quick meeting during AmSECT: Mike Hershkovitz, VP Global Sales

$IINN News: Inspira Expands U.S. Commercial Footprint! Inspira deploys INSPIRA™ ART100 at a premier New York Academic Medical Center, ranked Top 10 in NY State. This expands Inspira’s presence within the Tier-1 U.S. hospital market. Read more >> globenewswire.com/news-release/2…